covid-19 vaccine prevention infection

All eyes are now on Moderna’s covid-19 vaccine after Pfizer's success

Reading now: 559
www.livemint.com

Moderna Inc.’s market value has swelled by almost $24 billion this year on optimism that the biotech’s experimental messenger-RNA vaccine will play a part in tamping down the coronavirus pandemic.The company is expected to have an interim early look this month at how effective its shot, mRNA-1273, is at preventing Covid-19.

Results on Monday from Pfizer Inc. and BioNTech SE’s vaccine offered both boon and bane to Moderna. The shot set a high bar as a first look at their late-stage study showed more than 90% effectiveness is preventing symptomatic infections.

At the same time, vaccine similarities bode well for Moderna.Investors should expect more stock swings for Moderna, which has surged more than 280% this year.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA